Long-term results after ablation of infarct-related ventricular tachycardia

Oliver R Segal1, Anthony W C Chow, Vias Markides

  • 1St. Mary's Hospital and Imperial College of Medicine, London, United Kingdom.

Heart Rhythm
|April 21, 2005
PubMed

Insights

Catheter ablation effectively reduces implantable cardioverter-defibrillator (ICD) therapy for infarct-related ventricular tachycardia (VT). However, recurrence remains common, indicating ablation is adjunctive, not a substitute for ICDs.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Long-term outcomes of catheter ablation for infarct-related ventricular tachycardia (VT) are not well-defined.
  • Understanding the necessity and efficacy of implantable cardioverter-defibrillator (ICD) therapy post-ablation is crucial.

Purpose of the Study:

  • To evaluate the long-term effectiveness of catheter ablation in treating infarct-related VT.
  • To assess the subsequent need for ICD therapy after successful VT ablation.

Main Methods:

  • Utilized noncontact mapping to guide catheter ablation in 40 patients with infarct-related VT.
  • Mapped 140 VTs, targeting 81 for ablation, and monitored patients for recurrence and ICD shocks.

Main Results:

  • Achieved a high procedural success rate for VT ablation (82.7%), significantly reducing ICD shock frequency (from 6.8 to 0.05 shocks/month).
  • VT recurrence occurred in 7.5% of patients, with 37.5% experiencing new or recurrent VT/ventricular fibrillation (VF).
  • Only 42.5% of patients remained free from VT/VF at 3 years post-ablation.

Conclusions:

  • Noncontact mapping-guided VT ablation offers high success rates and reduces ICD therapy needs for infarct-related VT.
  • Catheter ablation serves as an important adjunctive therapy for symptomatic VT but does not replace ICDs or antiarrhythmic drugs.
  • Long-term VT/VF recurrence highlights the continued role of ICDs and medical management in these patients.
Abstract